Deepa Bhojwani, MD

Director, Leukemia and Lymphoma Program
Attending Physician; Hematology, Oncology and Blood and Marrow Transplantation
Associate Professor of Clinical Pediatrics, Keck School of Medicine of USC

Dr. Deepa Bhojwani is the Director of the Leukemia/Lymphoma Program within the Children’s Center for Cancer and Blood Diseases and actively participates in the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium. Following the completion of her Pediatric Hematology-Oncology Fellowship at New York University (NYU) Medical Center, Bhojwani was appointed instructor in Pediatric Hematology-Oncology at Mount Sinai and NYU Medical Centers.  She then served as an assistant member in the Department of Oncology at St. Jude Children’s Research Hospital from 2008 to 2015 before joining CHLA.

Clinical Interests

Relapsed acute lymphoblastic leukemia; Toxicities of leukemia therapy; Global Cancer Care


Medical School

St. Xavier’s College in Mumbai, India; M.S. Ramaiah Medical College, Bangalore, India, M.S. Ramaiah Medical College, Bangalore, India


Woodhull Medical Center, Brooklyn, New York


Woodhull Medical Center, Brooklyn, New York


New York University Medical Center, New York



Board-certified pediatric hematologist-oncologist


Children’s Oncology Group
American Society of Hematology

Medical Awards

Research Awards:

American Society of Clinical Oncology Merit Award 2004
Sidney Q. Cohlan, MD Research Seminar Award 2004



Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, Krull KR, Inaba H, Rubnitz JE, Metzger ML, Howard SC, Ribeiro RC, Cheng C, Reddick WE, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV: Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol, 2014; 32:949-59.

Bhojwani D, Pui CH: Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol, 2013; 14:e205-17. 

Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff S, Onciu M, Cheng C, Coustan-Smith E, Bowman WP, Howard SC, Metzger ML, Inaba H, Leung W, Evans WE, Campana D, Relling MV, Pui CH: ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia, 2012; 26:265-70.

Bhojwani D, Kang H, Menezes RX, Yang W, Sather H, Moskowitz NP, Min DJ, Potter JW, Harvey R, Hunger SP, Seibel N, Raetz EA, Pieters R, Horstmann MA, Relling MV, den Boer ML, Willman CL, Carroll WL, Children's Oncology Group, Dutch Childhood Oncology Group, German Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia: Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol, 2008; 26:4376-84.

Bhojwani D, Kang H, Moskowitz NP, Min DJ, Lee H, Potter JW, Davidson G, Willman CL, Borowitz MJ, Belitskaya-Levy I, Hunger SP, Raetz EA, Carroll WL: Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 2006; 108:711-7. 


Research Summary

Dr. Bhojwani is a board-certified, pediatric hematologist-oncologist. Her research background is in relapsed acute lymphoblastic leukemia (ALL) and includes studies of molecular pathways leading to relapse, identification of potential new therapeutic targets using high-throughput genomics, and follow-up validation studies in pre-clinical models.

In addition to patient care, she is involved in clinical research and developmental therapeutics for leukemias and lymphomas. She is the principal investigator for multiple phase I and II studies for ALL and collaborates with laboratory-based investigators to perform correlative biological studies on therapeutic protocols. In addition, she studies treatment-related and genetic risk factors in the development of toxicities (particularly neurotoxicity) during therapy of childhood ALL.

Bhojwani is extremely invested in international outreach efforts to improve care of children with cancer in countries with limited resources.

Research Studies

The goals of this study are to improve survival rates in children and young adults with relapsed AML through the combination of DEC and VOR.